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Prevention of Genital Herpes Simplex Virus Type 1
and 2 Disease in Mice Immunized with a gD-
Expressing Dominant-Negative Recombinant HSV-1
Richard Brans1, Natali V. Akhrameyeva1 and Feng Yao1
CJ9-gD is a novel herpes simplex virus (HSV) type 1 recombinant virus that is completely replication-defective,
expresses high-levels of HSV-1 major antigen glycoprotein D (gD), and can function in trans to inhibit
replication of wild-type HSV-1 and HSV-2 in co-infected cells. Here, we show that immunization with CJ9-gD
elicits strong and long-lasting humoral and Th1-like cellular immune responses against both HSV-1 and HSV-2.
Mice immunized with CJ9-gD exhibited significant reductions in the extent and duration of intravaginal
replication of challenge HSV-1 and HSV-2 compared with mock-immunized controls, and were completely
protected from local or systemic herpetic disease after intravaginal challenge with wild-type HSV-1 or HSV-2.
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INTRODUCTION
Genital herpes is a chronic, lifelong disease caused by herpes
simplex virus (HSV) that is characterized by unpredictable
recurrences. It is one of the most common sexually trans-
mitted diseases worldwide, and the primary cause of genital
ulcer disease in the developed and developing countries
(Mertz et al., 1998; Paz-Bailey et al., 2007). HSV-2 has been
the main cause for genital herpes, whereas HSV-1 has been
predominantly associated with orofacial infections, herpetic
keratitis, and herpes encephalitis (Liesegang, 1991; Whitley,
2006). However, more recently, it has been reported that
in developed countries HSV-1 is now the main causative
agent for primary genital herpes, especially among adoles-
cents, women, and homosexual men (Roberts, 2005; Jin et al.,
2006). The clinical signs of genital herpes are indistinguish-
able between HSV-1 and HSV-2 (Corey et al., 1983). After
primary genital infection, both HSV subtypes establish latent
infection in sacral dorsal root ganglia, subsequently giving
rise to intermittent reactivation. However, the frequency of
recurrent genital disease and asymptomatic viral shedding
is much higher for HSV-2 (Lafferty et al., 1987; Benedetti
et al., 1994). A potentially grave complication of genital
herpes is the transmission of HSV to neonates, which is often
associated with a high mortality rate and a high incidence of
neurological sequelae in survivors (Jones and Cunningham,
2004). Moreover, genital herpes increases the risk of acquiring
and transmitting HIV, which can be strongly reduced by
HSV-preventive or suppressive therapy (Wald and Link, 2002;
Freeman et al., 2007). To date, no medication can effectively
prevent primary as well as latent infection with HSV, and the
options for treatment and prevention of recurrences are very
limited (Whitley and Roizman, 2001). Experimental vaccine
approaches against genital herpes have mainly focused on
HSV-2 and included peptides, proteins, killed virus, DNA
vaccines, heterologous replicating viral vectors, replication-
defective viruses, and attenuated replication-competent
viruses (Bernstein and Stanberry, 1999; Koelle and Corey,
2003). However, in light of the general impact of HSV-1 and
the rising number of primary genital infections caused by this
subtype, a vaccine efficacious against both HSV-1 and HSV-2
is desirable.
The 155-kb genome for HSV-2 and the 152-kb genome for
HSV-1 show approximately 80% sequence homology, and
consist of a corresponding set of at least 74 genes (McGeoch
et al., 1988; Dolan et al., 1998). Owing to their similarity
HSV-1 and HSV-2 cross-react antigenically and elicit type-
common immune responses. Although it is unclear whether
pre-existing immunity to HSV-1 in humans protects against
the HSV-2 infection (Bryson et al., 1993; Looker and Garnett,
2005), individuals seropositive for HSV-1 are reported to be
more likely to have asymptomatic HSV-2 seroconversion
than HSV-seronegative persons (Langenberg et al., 1999). In
mouse and guinea pig models of genital herpes, it has been
shown that several vaccine candidates, including whole
virus, and replication-conditional or replication-defective
HSV of one subtype, are also capable of eliciting protective
type-common immune responses against the other subtype
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One of the main targets for subunit vaccines (viral as well
as plasmid-based vaccines) has been the major HSV antigen
glycoprotein D (gD). Although subunit vaccines containing
gD in combination with an adjuvant seemed to be safe and
effective in the animal models of genital herpes (Stanberry
et al., 1987; Bourne et al., 2005), they failed to provide
general protection in clinical trials (Corey et al., 1999;
Stanberry et al., 2002). Replication-defective viruses lacking
functions essential for viral replication or assembly of
infectious progeny virus particles elicit a broad spectrum of
protective immune responses against HSV in mice and
guinea pigs without causing the disease (Dudek and Knipe,
2006). However, the use of replication-defective viruses,
particularly when used in latently infected individuals,
imposes certain risks, as they might regain replication
competence in the presence of wild-type virus or reactivate
latent wild-type virus infections.
In an effort to minimize these safety concerns, using the
T-REx (Invitrogen, Carlsbad, CA) gene switch technology and
the dominant-negative mutant polypeptide, UL9-C535C, of
HSV-1 origin-binding protein, UL9, we developed a UL9-
C535C-encoding HSV recombinant virus, CJ83193, capable
of preventing its own viral DNA replication, as well as that of
wild-type HSV-1 and HSV-2 in co-infected cells (Yao and
Eriksson, 1999, 2002). Although infection of cells with
CJ83193 can lead to expression of viral immediate-early
(a), early (b), and certain early-late gene (g1) products, little
gD is detected in CJ83193-infected cells (Augustinova et al.,
2004). Aiming to further increase its safety and improve its
efficacy as a vaccine against HSV, we recently constructed a
CJ83193-derivative viral recombinant, CJ9-gD, in which the
essential UL9 gene is replaced by an extra copy of the HSV-1
gD (gD1) gene under the control of the tetracycline operator
sequence-bearing human cytomegalovirus major immediate-
early promoter (Brans et al., 2008; Lu et al., 2009). Thus, CJ9-
gD is completely replication-defective, expresses high-level
of gD, and causes no detectable latent infection after ocular
or nasal infection in mice (Lu et al., 2009). In a mouse model
of HSV-1 ocular infection, we showed that CJ9-gD is more
effective than CJ83193 in inducing protective immune
responses against wild-type HSV-1 challenge (Lu et al.,
2009) and protects guinea pigs against HSV-1 skin disease
(Brans et al., 2008). We further show that immunization with
CJ9-gD elicits strong HSV-1 neutralization antibody (Ab)
response, as well as HSV-1-specific CD4þ and CD8þ T-cell
response at levels similar to that seen in wild-type HSV-1-
immunized mice (Lu et al., 2009).
Here, we evaluate the efficacy of the HSV-1 recombinant
virus, CJ9-gD, as a prophylactic vaccine against wild-type
HSV-1 and HSV-2 in a mouse model of genital infection.
RESULTS
HSV-1
Dose-dependent induction of HSV-1-specific neutralizing
Abs in mice immunized with CJ9-gD. The ability of CJ9-gD to
elicit anti-HSV-1-specific neutralizing Abs was first deter-
mined in mice immunized with CJ9-gD at a dose of
2106 PFU (plaque-forming unit), and then at reduced doses
of 5105 and 1105 PFU. As control, a group of mice was
also immunized with CJ83193 at a dose of 5105 PFU. The
HSV-1-specific neutralization Ab titers in mice immunized
with 2 106 PFU of CJ9-gD 2 weeks after the second
immunization were on average 4,800 (Figure 1a). HSV-1-
specific neutralization Ab titers after immunization with
5105 PFU of CJ83193 were 800, twofold and fourfold
lower than those of mice immunized with 1 105 or
5105 PFU of CJ9-gD, respectively (Figure 1a). No specific
Ab titers against HSV-1 were detected in the mock-
vaccinated mice at a 1:10 dilution.
The effectiveness of CJ9-gD in inducing long-term anti-
HSV-specific neutralizing Ab response was evaluated at 6
months after primary immunization and compared with that
elicited after immunization with the same dose of the wild-
type HSV-1, strain KOS (Figure 1b). The titer of HSV-1-
specific neutralization Abs in mice immunized with
2106 PFU of CJ9-gD was 3,600, which is comparable with
that after immunization with KOS, and that detected 2 weeks
after the second immunization with 2106 PFU of CJ9-gD.
Induction of HSV-1-specific long-term cytokine response in
mice immunized with CJ9-gD. We earlier showed that
immunization with CJ9-gD elicited strong HSV-1-specific
Th1 T-cell response (Lu et al., 2009). To evaluate the long-
term effect of cellular immune responses induced by CJ9-gD,
mice were mock-immunized with DMEM or immunized with
2106 PFU of KOS or CJ9-gD. After 6 months splenocytes
were isolated and cultured for 72 hours in the presence or
absence of UV-inactivated HSV-1. Figure 1c show that
significantly higher levels of HSV-1-specific IFN-g and IL-2
expression were detected in splenocytes from CJ9-gD-
immunized mice than from the mock-immunized controls
(Po0.05). The degrees of IFN-g and IL-2 response detected in
KOS-immunized mice were higher than those of CJ9-gD-
immunized mice after stimulation with UV-inactivated HSV-
1, but these differences did not reach significance. Levels of
IL-4 were low for all the groups.
Protection against HSV-1 genital infection in immunized
mice. At 4 weeks after the initial immunization, two sets of
mice (n¼ 6; n¼17), which were either mock-immunized or
immunized with 2 106 PFU of CJ9-gD, and another set of
mice (n¼32), which were mock-immunized or immunized
with CJ9-gD at doses of 1105 or 5 105 PFU, or CJ83193 at
a dose of 5105 PFU, were challenged intravaginally with
HSV-1 strain, mP. Vaginal swabs were taken on days 1, 2, 3,
5, and 7 after challenge. The yields of challenge virus were
significantly lower in mice immunized with 2106 PFU of
CJ9-gD compared with those in mock-immunized mice, with
a reduction of more than 280-fold on day 1 (Po0.005) and
1,800-fold on day 2 (Pp0.001) (Figure 2a). By day 3 no
challenge virus was detected in CJ9-gD-immunized mice,
whereas all mock-vaccinated mice continued to shed virus at
an average yield of more than 3.6104 PFUml1. The
average duration of viral shedding in immunized mice was
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1.25 days as compared with 6.1 days in the mock-immunized
mice (Po0.0001) (Figure 2b).
Immunization with the lower dose of 5105 PFU of CJ9-
gD also significantly reduced the viral titer of challenge virus
recovered from vaginal swabs on day 1 (Po0.05) and day 2
(Po0.01) compared with those from mock-immunized mice
(Figure 2c). No virus was detected in mice immunized with
5105 PFU of CJ9-gD by day 3, whereas at the same time all
mock-vaccinated mice continued to shed virus at an overall
average yield of 1.7105 PFUml1 (Po0.05). Immunization
with 5105 PFU of CJ83193 also led to a significant
reduction in challenge virus replication on days 1 (Pp0.05)
and 2 (Po0.05), but the average titers of challenge virus was
significantly higher than those found in mice immunized with
5105 PFU of CJ9-gD (day 1: Po0.01 and day 2: Po0.001)
(Figure 2c). The duration of viral shedding was decreased to
an average of 1.4 days after immunization with 5 105 PFU
of CJ9-gD, which was significantly shorter than the average of
3.6 days of viral shedding observed in mice immunized with
5105 PFU of CJ83193 (Po0.001) or in mock-immunized
controls (Po0.0001) (Figure 2d). Immunization with the
lower dose of 1105 PFU of CJ9-gD led to a significant
reduction in challenge virus replication on day 3 (Po0.05),
whereas no challenge virus was detected by day 5 post-
challenge with duration of virus shedding for 2.8 days in
average.
Mice immunized with 2106 PFU of CJ9-gD were
completely protected from the development of local genital
lesions and exhibited no signs of systemic disease after
challenge with wild-type HSV-1, whereas 100% of mock-
vaccinated mice developed severe genital lesions after
challenge with the wild-type HSV-1 (Figure 3a). A total of,
8 of 11 mice (73%) developed hind limb paralysis, and
eventually succumbed to the challenge of infection (Figure
3b). After immunization with 1 105 and 5 105 PFU of CJ9-
gD, or with 5105 PFU of CJ83193, mice were again
completely protected from signs of local or systemic HSV-1
disease. The control group of mock-immunized mice
exhibited a morbidity and mortality comparable with those
described above (Figure 3c and d).
Protection from latent HSV-1 infection. To compare the
ability of CJ9-gD to prevent accumulation of latent challenge
virus with that of CJ83193, the lower spinal column,
including spinal cord and dorsal root ganglia, were harvested
30 days after intravaginal challenge with 5105 PFU of
HSV-1 strain mP from 16 mice immunized either with CJ9-gD
or CJ83193 at a dose of 5105 PFU. The whole DNA was
extracted and tested for latent viral DNA using quantitative
real-time PCR. The average amount of latent HSV DNA per
mouse was significantly higher in mice vaccinated with
CJ83193 than in CJ9-gD-immunized animals (69.8 vs 23.2
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Figure 1. Induction of herpes simplex virus (HSV)-1-specific neutralizing antibodies (Abs) and T-cell responses in immunized mice. (a) Three sets of BALB/c
mice (n¼ 6; n¼ 17; n¼ 17) were injected with 2106 PFU per mouse of CJ9-gD or DMEM. Two sets of 32 BALB/c mice (eight mice per group) were mock-
vaccinated with DMEM, or vaccinated with CJ9-gD or CJ83193 at the indicated doses. At 4 weeks after primary immunization, the blood was collected and
pooled for each group, and HSV-1-specific neutralizing Ab titers were determined. The results represent average titers±SEM. (b) BALB/c mice were mock-
immunized with DMEM (n¼2) or immunized with either KOS (n¼ 5) or CJ9-gD (n¼ 4) at 2 106 PFU per mouse. AT 6 months after the primary immunization,
blood and splenocytes were collected individually from each mouse. Serum was assayed for HSV-1-specific neutralizing Ab titers. (c) Splenocytes from mice
described in (b) were cultured in the presence or absence of UV-inactivated HSV-1 strain McKrae. Levels of IFN-g, IL-2, and IL-4 in supernatants were
determined by ELISA. The results represent average cytokine levels after subtraction of background values from mock-stimulated wells±SEM. P-values were
assessed by student’s t-test (*Po0.05).
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DNA copies, Po0.05, Figure 4). As a control, the same
procedure was carried out in eight mice 30 days after the
second immunization with 2106 PFU of either CJ9-gD or
CJ83193, which were, however, not challenged with wild-
type HSV. No latent viral DNA was detected in these two
groups of mice, indicating that neither virus can establish
detectable latent infection after s.c. (subcutaneous) injection,
and that the viral DNA detected in dorsal root ganglia after
challenge with wild-type HSV-1 was indeed the challenge
wild-type HSV viral DNA.
HSV-2
Induction of HSV-2-specific Ab and T-cell responses in mice
immunized with CJ9-gD. Given the effectiveness of CJ9-gD
immunization in preventing HSV-1 infection, we next
examine the ability of CJ9-gD to elicit anti-HSV-2 cross-
specific neutralizing Abs. The HSV-2-specific neutralization
Ab titers in mice immunized with 2106 PFU of CJ9-gD 2
weeks after the second immunization were on average 600
(Figure 5a). The titer of HSV-2-specific neutralization Abs
after immunization with 1 105 or 5 105 PFU of CJ9-gD
was 400 and 800, respectively (Figure 5a). The HSV-2
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Figure 2. Reduction of challenge herpes simplex virus (HSV)-1 vaginal
replication in mice immunized with CJ9-gD. One set of six and another set of
17, 6-week-old female BALB/c mice were subcutaneously (s.c.) inoculated
with either 2 106 PFU per mouse of CJ9-gD or DMEM (a and b). BALB/c
mice (eight mice per group) were inoculated s.c. with either 1105 PFU of
CJ9-gD, 5105 PFU of CJ9-gD, 5 105 PFU of CJ83193, or DMEM (c and d).
Mice were boosted after 2 weeks. At 4 weeks, mice were pretreated with
medroxyprogesterone and challenged intravaginally with 5 105 PFU of
HSV-1 strain mP. Vaginal swabs were taken on days 1, 2, 3, 5, and 7 post-
challenge. Infectious viruses in swab materials were assessed by standard
plaque assay on Vero cell monolayers. Viral titers are expressed as the
mean±SEM in the individual vaginal swabs (a and c). The duration of viral
shedding is represented as the mean number of days during which infectious
virus was detected in swab material after challenge±SEM (b and d). P-values
were assessed by student’s t-test (*Po0.05, **Po0.01, ***Po0.005,
KPo0.001, KKPo0.0005, KKKPo0.0001)
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Figure 3. Prevention of herpes simplex virus (HSV)-1 disease in mice
immunized with CJ9-gD or CJ83193. After challenge with wild-type HSV-1,
individual mice described in the legend of Figure 2 were observed during a
30-day follow-up period for the incidence of genital and disseminated HSV-1
disease (a and c), and survival (b and d) using the following score: 0¼ no sign,
1¼ slight genital erythema and edema, 2¼moderate genital inflammation,
3¼ purulent genital lesions, 4¼ hind-limb paralysis, 5¼ death.
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Figure 4. CJ9-gD is more effective than CJ83193 in preventing latent herpes
simplex virus (HSV)-1 infection.One set of 16 female 6- to 8-week-old BALB/
c mice was subcutaneously injected either with 5105 PFU of CJ9gD or with
5 105 PFU of CJ83193, and boosted after 2 weeks. At 4 weeks, the mice
were pretreated with medroxyprogesterone and challenged intravaginally
with 5105 PFU of HSV-1 strain mP. At 30 days after challenge, lower spinal
column, including spinal cord and dorsal root ganglia, were harvested, the
whole DNA was extracted and examined for the presence of latent viral DNA
by quantitative real-time PCR. The results represent the mean amount of viral
DNA per animal±SEM. P-value was assessed by student’s t-test (*Po0.05).
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cross-specific neutralizing Abs in mice immunized with
5105 PFU of CJ83193 was 400, two fold lower than that
in mice immunized with the same dose of CJ9-gD. No
specific Ab titers against HSV-2 were detected in the mock-
vaccinated mice at a 1:10 dilution.
The long-term anti-HSV-2-specific neutralizing Ab
response was evaluated at 6 months after primary immuniza-
tion (Figure 5b). The titer of HSV-2-specific neutralization
Abs in mice immunized with 2106 PFU of CJ9-gD was 500,
which is comparable with that after immunization with KOS.
We next examined the effectiveness of CJ9-gD in the
induction of HSV-2 cross-specific T-cell immune response
with cytokine assays (Figure 6a), as well as CD4þ T cell
(Figure 6b) and CD8þ T cell (Figure 6c) IFN-g ELISPOT
assays. Figure 6a shows that lymphocytes from mice
immunized with KOS produced higher levels of anti-HSV-2-
specific IL-2 and similar levels of IFN-g responses compared
with those detected in CJ9-gD-immunized mice. Levels of IL-4
were low and no significant difference was detected among
the vaccinated and mock-vaccinated controls.
IFN-g ELISPOT assays show that immunization with CJ9-
gD elicited an HSV-2-specific CD4þ T-cell response yielding
58-fold more IFN-g spot-forming cells than the mock-
immunized controls (Figure 6b, P¼0.002). An HSV-2
cross-specific CD8þ T-cell response is also elicited in CJ9-
gD-immunized mice compared with mock-immunized con-
trols (Figure 6c, P¼0.001). Taken together, the results show
that immunization with CJ9-gD can effectively elicit HSV-2
cross-specific Th1 T-cell response.
Protection against HSV-2 genital infection in immunized
mice. The results in Figure 7a show that the ability of
challenge virus to replicate in vaginal mucosa was signifi-
cantly reduced from day 1 to day 5 (Po0.001, days 1, 2, and
5; Po0.05, day 3) in mice immunized with 2106 PFU of
CJ9-gD compared with those in mock-immunized mice. The
challenge virus infection had resolved by day 7 in the
immunized mice, whereas at the same time all mock-
immunized mice continued to shed virus at an average yield
of more than 7.6102 PFUml1 (Figure 7a). Compared
with mock-immunized mice, the average duration of viral
shedding in the immunized mice decreased significantly from
7 days to 2.8 days (Po0.0005) (Figure 7b).
Immunization with a lower dose of 5105 PFU of CJ9-gD
also led to a significant reduction in the viral titer recovered
from the vaginal swabs after challenge with wild-type HSV-2
on days 2 (Po0.05), 3 (Po0.005), and 5 (Po0.001)
compared with those of mock-immunized mice (Figure 7c).
Although immunization with 1 105 PFU of CJ9-gD reduced
viral titers significantly compared with mock-immunized
mice on days 3 (Po0.01) and 5 (Po0.001), it was notably
less effective than immunization with 5105 PFU of CJ9-gD
(Figure 7c). The average duration of viral shedding after
immunization with 5105 or 1105 PFU of CJ9-gD was 3.5
days and 4.25 days, respectively, which was significantly
shorter than that of mock-immunized controls (Po0.005)
(Figure 7d).
As shown in Figure 8, mice immunized with 2 106 PFU
of CJ9-gD were completely protected from development of
local genital lesions and exhibited no signs of systemic
disease after challenge with wild-type HSV-2. All mock-
vaccinated mice developed severe genital lesions followed
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Figure 6. Induction of herpes simplex virus (HSV)-2 cross-specific cytokine
response in immunized mice. Cytokine assays (a). Splenocytes from BALB/c
mice mock-immunized with DMEM (n¼ 4), or immunized with 2 106 PFU
per mouse of KOS (n¼ 4) or with CJ9-gD (n¼ 4) were isolated from individual
mice, and cultured in the presence or absence of UV-inactivated HSV-2 strain
186. Levels of IFN-g, IL-2, and IL-4 in the supernatants were assessed by
ELISA. The results represent average cytokine levels after subtraction of
background values from mock-stimulated wells±SEM (a). IFN-g ELISPOT
assays (b and c). Splenocytes from BALB/c mice mock-immunized with
DMEM (n¼ 2) or immunized with 2106 PFU per mouse of KOS (n¼ 4) or
with CJ9-gD (n¼ 4) were prepared individually. (b) CD4þ T cells were
seeded in plates precoated with IFN-g-specific MAb and stimulated with
mock-infected or UV-inactivated HSV-2-infected syngeneic CD11cþ bone
marrow-derived dendritic cells. (c) CD8þ T cells were seeded in plates
precoated with IFN-g-specific MAb and stimulated with mock-infected or
HSV-2-infected syngeneic CL7 cells. The HSV-2-specific IFN-g spot-forming
cells are expressed as the mean±SEM per million CD4þ T cells (b) or
splenocytes (c) from four mice per group. P-values were assessed by student’s
t-test (*Po0.005, **Pp0.001).
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by hind limb paralysis and eventually succumbed to the
challenge of infection (Figure 8b). Among mice immunized
with 5105 PFU of CJ9-gD, two mice (25%) developed signs
of clinical disease, of which one (12.5%) was killed due to
systemic involvement (Figure 8c and d). Overall, mice
immunized with 1 105 PFU of CJ9-gD had a higher disease
score than mice immunized with 5 105 PFU of CJ9-gD and
only 60% of mice survived the challenge with wild-type
HSV-2.
DISCUSSION
Genital herpes is mainly caused by HSV-2, but recently,
rising numbers of primary infections due to HSV-1 have
indicated a great need for a vaccine against both HSV-1 and
HSV-2 (Langenberg et al., 1999; Xu et al., 2006).
In the early phase after vaginal infection of mice and
guinea pigs, HSV is targeted by specific Abs and cellular
immunity, thereby limiting acute infection and spreading,
whereas clearance of HSV from the genital mucosa as well as
immune control of latency is primarily mediated by T cells
and Th1-associated cytokines such as IFN-g (Stanberry et al.,
2000; Koelle and Corey, 2003). Therefore, the effective
prevention of HSV genital disease may be accomplished by a
vaccine inducing both humoral and cellular immune
responses against HSV-1 and HSV-2. This study shows that
immunization of mice with the HSV-1 recombinant virus,
CJ9-gD, is capable of eliciting long-lasting and high-level
neutralizing Abs and Th1-like cellular immune responses
against HSV-1 and, to a lesser extent, against HSV-2.
Notably, HSV-1- and HSV-2-specific neutralization Ab titers
detected at 2 weeks (data not shown) and 6 months after the
second immunization with 2106 PFU of CJ9-gD were
essentially similar to those achieved after immunization with
HSV-1 wild-type strain KOS at the same dose, indicating that
CJ9-gD is as efficient as wild-type HSV-1 in inducing humoral
immune responses against HSV-1 and HSV-2. In addition, as
assessed by IFN-g-ELISPOT assays, immunization with CJ9-
gD induced strong HSV-2-specific cellular immune responses
by CD4þ and CD8þ T cells.
Compared with mock-immunization, immunization with
2106 or 5 105 PFU of CJ9-gD significantly reduced the
amount and duration of acute vaginal replication of wild-type
HSV-1 after challenge and provided complete protection
against genital herpes. Furthermore, immunization with CJ9-
gD at these two doses also significantly reduced the amount
and duration of acute replication of wild-type HSV-2 after
vaginal challenge compared with mock-immunization. At an
immunization dose of 2106 PFU of CJ9-gD, mice were
completely protected from HSV-2 disease, whereas at the
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Figure 7. Reduction of challenge herpes simplex virus (HSV-2) vaginal
replication in mice immunized with CJ9-gD. One set of 17 female BALB/c
mice were subcutaneously (s.c.) injected either with 2106 PFU per mouse
of CJ9-gD or with DMEM (a and b). One set of 24 female 6- to 8-week-old
BALB/c mice was injected s.c. either with 1105 PFU of CJ9-gD, 5 105 PFU
of CJ9-gD, or with DMEM (c and d). Mice were boosted after 2 weeks. At 4
weeks, mice were pretreated with medroxyprogesterone and challenged
intravaginally with 1 105 PFU of HSV-2 strain 186. Vaginal swabs were
taken on days 1, 2, 3, 5, and 7 post-challenge. Infectious viruses in the swab
materials were assessed by standard plaque assay on Vero cell monolayers.
Viral titers are expressed as the mean±SEM in the individual vaginal swabs (a
and c). The duration of viral shedding is represented as the mean number of
days during which injections virus was detected in swab material after
challenge±SEM (b and d). P was assessed by student’s t-test (*Po0.05,
**Po0.01, ***Po0.005, KPo0.001, KKPo0.0005).
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Figure 8. Prevention of herpes simplex virus (HSV)-2 disease in mice
immunized with CJ9-gD. After challenge with wild-type HSV-2, individual
mice described in the legend of Figure 7a and b (a and c) and mice described
in the legend of Figure 7c and d (b and d), were observed during a 30-day
follow-up period for the incidence of genital and disseminated HSV-1 disease
(a and c), and survival (b and d) using the following scale: 0¼no sign,
1¼ slight genital erythema and edema, 2¼moderate genital inflammation,
3¼ purulent genital lesions, 4¼ hind-limb paralysis, 5¼ death.
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lower immunization dose of 5105 PFU of CJ9-gD 25% of
mice developed signs of local disease, of which 50% (n¼ 1)
progressed to disseminated disease. Taken together, these
data indicate that in addition to its good protection against
genital challenge with HSV-1, immunization with the HSV-1
recombinant virus, CJ9-gD, elicits a dose-dependent cross-
immunity against genital challenge with HSV-2. The mouse
model of genital HSV infection does not allow us to directly
assess the effect of immunization with CJ9-gD on latent
infection or recurrent disease because of the high mortality
rate in the mock-vaccinated mice and the lack of sponta-
neous recurrences after genital challenge with wild-type
HSV. We have recently investigated the efficacy of CJ9-gD as
a vaccine against primary and recurrent HSV-2 genital
disease in guinea pigs, showing that CJ9-gD immunization
can prevent recurrent HSV-2 disease and significantly reduce
the latent challenge viral DNA load in immunized animals
compared with that of mock-vaccinated controls (Brans and
Yao, unpublished data). This is consistent with our earlier
data, showing that after skin challenge with wild-type HSV-1
the amount of latent HSV-1 challenge virus was significantly
lower in dorsal root ganglia of guinea pigs immunized with
CJ9-gD compared with those of mock-vaccinated controls
(Brans et al., 2008).
CJ9-gD seems more effective in inducing protective
immune responses against HSV-1 than against HSV-2. This
finding is consistent with earlier reports that HSV vaccines are
generally less effective in prevention of heterotypic HSV
infection than homotypic infection (Erturk et al., 1989;
McLean et al., 1994; Boursnell et al., 1997; Da Costa et al.,
2001). It is reasonable to speculate that immunization with an
HSV-2 recombinant virus containing the same features, as
CJ9-gD will likely provide a greater effectiveness against
challenge with wild-type HSV-2 than the current HSV-1
recombinant virus.
We earlier showed that CJ9-gD elicits stronger immune
responses against HSV-1 keratitis in mice than CJ83193, and
is more effective than CJ83193 in prevention of reactivation of
challenge virus from latent infection (Lu et al., 2009). This
study extents this finding, showing that although immuniza-
tion with CJ9-gD or CJ83193 lead to a marked decrease in the
amounts and duration of acute vaginal replication of HSV-1
challenge virus and prevents genital herpetic disease,
CJ83193 was significantly less effective than CJ9-gD in
limiting the acute vaginal replication of HSV-1 in the
immunized mice. There are greater than 6,000-fold more
challenge HSV-1 detected in vaginal swabs of mice immu-
nized with CJ83193 than in swabs from CJ9-gD-immunized
mice on day 3 post-challenge, and an average of a 2-day
longer period of viral shedding was detected in CJ83193-
immunized mice than mice immunized with CJ9-gD.
Furthermore, CJ9-gD was significantly better in limiting latent
infection of lumbosacral dorsal root ganglia by challenge
HSV-1 than CJ83193. As reduction of latent viral load is
associated with a lower risk of reactivation (Lekstrom-Himes
et al., 1998; Sawtell, 1998), this observation further indicates
that CJ9-gD is more effective than CJ83193 as a vaccine
against HSV-1 infection. The expression of gD by CJ9-gD
significantly enhances its ability to elicit anti-HSV-1-specific
neutralizing Abs compared with CJ83193 (Lu et al., 2009),
whereas similar levels of HSV-1-specific Th1 cytokine
response were detected between mice immunized with CJ9-
gD and CJ8319 (Lu et al., 2009), suggesting that induction of a
stronger neutralizing Ab response may have a large impact on
the observed superiority of CJ9-gD as a vaccine against HSV-
1. It should be noted that we detected no significant difference
between the efficacy of CJ9-gD and CJ83193 as a vaccine in
prevention of HSV-2 genital infection at a dose of 5 105 PFU
per mouse (data not shown), indicating that expression of gD1
by CJ9-gD is less important in eliciting overall protective
immunity against HSV-2 than against HSV-1 in mice.
Taken together, our results show that CJ9-gD is capable of
eliciting strong and long-lasting humoral and cellular
immune responses against both HSV-1 and HSV-2 in mice.
The level of immunity and cross-immunity is sufficient to
significantly reduce the amount and duration of acute vaginal
replication, and protects the mice from genital and dissemi-
nated disease caused by either HSV-1 or HSV-2. Given that
immunization with CJ9-gD protects mice from HSV-1 ocular
disease and guinea pigs from HSV-1 cutaneous infection, we
conclude that CJ9-gD is a safe and effective vaccine against a
range of HSV-associated diseases of both subtypes in rodents.
MATERIALS AND METHODS
Cells and viruses
African Green Monkey Kidney (Vero) cells were grown and
maintained in DMEM (Sigma Aldrich, St Louis, MO) supplemented
with 10% fetal bovine serum in the presence of 100Uml1 penicillin
G and 100mgml1 streptomycin sulfate (Invitrogen, Carlsbad, CA)
(Yao and Schaffer, 1995). RUL9-8 cells, U2OS cells expressing UL9
and tetracycline repressor (tetR), were grown and maintained in
DMEM plus 10% fetal bovine serum supplemented with hygromycin
B (50mgml1) and G418 (400mgml1) (Yao et al., 2006).
Wild-type HSV-1 strain mP and HSV-2 strain 186 were
propagated and plaque-assayed on Vero cells. Both viruses were
the kind gift of David M. Knipe (Harvard Medical School). mP is a
virulent strain of HSV-1 that has been used earlier as a challenge
virus for HSV-1 vaccine studies (Nguyen et al., 1992; Morrison and
Knipe, 1994; Augustinova et al., 2004). CJ83193 is a dominant-
negative and replication-impaired virus, in which both copies of the
HSV-1 ICP0 gene in strain KOS are replaced by DNA sequences
encoding the dominant-negative HSV-1 polypeptide, UL9-C535C,
under the control of the tetracycline operator sequence-bearing
human cytomegalovirus major immediate-early promoter (Yao and
Eriksson, 1999). CJ9-gD was derived from CJ83193 by replacing the
essential UL9 gene with the HSV-1 gD gene driven by the
tetracycline operator sequence-containing human cytomegalovirus
major immediate-early promoter (Brans et al., 2008; Lu et al., 2009).
No infectious virus was detected in Vero cells when a total of
1.1 108 PFU of CJ9-gD virus was plaque-assayed. CJ9-gD was
propagated and assayed in RUL9-8 cells.
Mice
Female BALB/c mice 6–8 weeks of age were purchased from Charles
River Laboratories (Wilmington, MA). Mice were housed in metal
cages at four mice per cage and maintained on a 12 hours light–dark
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cycle. Mice were allowed to acclimatize to the housing conditions
for 1 week before experimentation. All animal experiments were
conducted according to the protocols approved by Harvard Medical
Area Standing Committee on Animals and the American Veterinary
Medical Association.
Immunization and challenges
BALB/c mice were randomly divided into several groups and the hair
on their left rear flank was trimmed. One set of six and two sets of 17
mice were either vaccinated with 2 106 PFU per mouse of CJ9-gD
or mock-vaccinated with DMEM in a volume of 20 ml s.c. in the left
rear flank using a 1-ml syringe fitted with a 27-gauge needle. Mice
were boosted after 2 weeks and challenged with wild-type virus 4
weeks after primary immunization. At 5 days before challenge, mice
were injected s.c. in the neck ruff with medroxyprogesterone (SICOR
Pharmaceuticals Inc., Irvine, CA) at 3mg per mouse in a volume of
20 ml. For intravaginal challenge, mice in all groups were anesthe-
tized and preswabbed with a calcium alginate swab (Fisher
Scientific, Waltham, MA). One set of six mice and another set of
17 mice were inoculated intravaginally with 20 ml of culture medium
containing 5 105 PFU of HSV-1 strain mP. Another set of 17 mice
was inoculated intravaginally with 20ml of culture medium contain-
ing 1 105 PFU of HSV-2 strain 186. Animals were kept on their
backs with their rear part elevated under the influence of anesthesia
for 30–45minutes post-infection.
Comparison of CJ9-gD and CJ83193
Two sets of 32 BALB/c mice were either vaccinated with
1 105 PFU per mouse of CJ9-gD, 5 105 PFU per mouse of CJ9-
gD, 5 105 PFU per mouse of CJ83193 or mock-vaccinated with
DMEM, boosted after 2 weeks and challenged intravaginally with
5 105 PFU of HSV-1 strain mP, as described above.
Assay of acute infection
On days 1, 2, 3, 5, and 7 post-challenge, vaginal mucosae were
swabbed with a moist calcium alginate swab (Fisher Scientific),
which was kept in 1ml DMEM, and stored at 801C until assayed
for infectious virus by standard plaque assay on Vero cell
monolayers.
Clinical observation
After challenge with wild-type HSV-1 and HSV-2, mice were
observed daily during a 30-day follow-up period for signs of genital
lesions and systemic illness. The severity of disease was scored as
follows: 0¼ no sign, 1¼ slight genital erythema and edema,
2¼moderate genital inflammation, 3¼ purulent genital lesions,
4¼ hind-limb paralysis, 5¼ death.
Detection of HSV-1- and HSV-2-specific neutralizing Abs
Blood was collected from tail veins of immunized and mock-
immunized mice 4 weeks after primary immunization. Neutralizing
serum Ab titers were determined as described earlier in the presence
of complement (Bourne et al., 1996; Augustinova et al., 2004)
with either 250 PFU of wild-type HSV-1 strain mP or 200 PFU of
wild-type HSV-2 strain 186. The neutralizing titer was expressed
as the final serum dilution required to achieve a 50% reduction in
HSV PFU relative to the HSV PFU obtained in medium plus
complement alone.
Long-term effect of vaccination
A total of, 11 female BALB/c mice 6–8 weeks of age were randomly
divided into three groups, and immunized s.c. with either wild-type
HSV-1 strain KOS (n¼ 5) or CJ9-gD (n¼ 4) at 2 106 PFU per
mouse, or mock-vaccinated with DMEM (n¼ 2). Mice were boosted
2 weeks after primary immunization. At 6 months after the primary
immunization, mice were sacrificed, blood was taken for neutraliza-
tion Ab assays and spleens were harvested for cytokine assays.
Cytokine assays
A total of 12 female BALB/c mice 6–8 weeks of age were randomly
divided into three groups, and immunized s.c. with either KOS or
CJ9-gD at 2 106 PFU per mouse, or mock-vaccinated with DMEM.
Mice were boosted 2 weeks after primary immunization. At 2 weeks
after the second immunization, splenocytes were isolated and
seeded into 24-well plates at 1.5 106 cells per well in a volume
of 1ml (Lu et al., 2009). Cells were either mock-stimulated with
medium or stimulated with UV-inactivated HSV-2 strain 186 at a
multiplicity of infection of 5 PFU per cell, according to the titer
before UV inactivation. For the long-term effect of vaccination, one
set of cells was stimulated with UV-inactivated HSV-1 strain McKrae
at a multiplicity of infection of 5 PFU per cell. After incubation at
371C for 72 hours, supernatants were collected and stored at 801C.
Levels of IFN-g, IL-2, and IL-4 expression were determined with
the Endogen Mouse Colorimetric ELISA Kits (Fisher Scientific,
Waltham, MA).
IFN-c ELISPOT assays
Splenocytes were isolated from individual female Balb/c mice 10–12
weeks after mock-immunization or primary immunization with
2 106 PFU of KOS (n¼ 4) or 2 106 PFU of CJ9-gD (n¼ 4). The
CD4þ T cell ELISPOT assay and the CD8þ T cell ELISPOT assay
were carried out as described earlier (Lu et al., 2009). For the CD4þ
T cell ELISPOT assay, T cells, isolated from splenocytes using Dynal
mouse CD4-negative isolation kit (Invitrogen, Carlsbad, CA), in
triplicates were stimulated either with mock-infected or with UV-
inactivated HSV-2 strain 186-infected (5 PFU per cell), and with
mitomycin C-treated (50 mgml1) syngeneic CD11cþ bone marrow-
derived dendritic cells at responder-to-stimulator ratios of 5:1 and
10:1, respectively. For the CD8þ T cell ELISPOT assay, cells in
triplicate were stimulated with either mock-infected or HSV-2 strain
186-infected (1 PFU per cell), and mitomycin C-treated (50 mgml1)
syngeneic CL7 cells (ATCC, Manassas, VA) at responder-to-
stimulator ratios of 2:1 and 5:1, respectively. Spots were counted
in a dissecting microscope and the number of HSV-1-specific IFN-g
spot-forming cells was expressed as the mean±SEM per million
splenocytes minus the spot-forming cells detected in the correspond-
ing control wells stimulated with mock-infected bone marrow-
derived dendritic cells or CL7 cells.
Quantitative real-time PCR
The lower lumbar and sacral part of the spinal column, including
spinal cord and dorsal root ganglia, were collected 30 days after
intravaginal challenge with 5 105 PFU of HSV-1 strain mP from 16
mice that had been either immunized with 5 105 PFU of CJ9-gD or
with 5 105 PFU of CJ83193. The spinal column was cut into four
pieces and each piece was kept separately in 0.5ml of normal
growth medium and stored at 801C for further processing. Total
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DNA was isolated from each dorsal root ganglion using the DNeasy
tissue kit (Qiagen, Santa Clarita, CA), and suspended in 60 ml AE
buffer. The presence of HSV-1 DNA was quantified by real-time PCR
with a pair of primers specific to the HSV-1 DNA polymerase
(Forward: 50-GCT CGA GTG CGA AAA AAC GTT C, Reverse:
50-CGG GGC GCT CGG CTA AC) as described earlier (Brans et al.,
2008). The minimal copies of HSV-1 viral DNA that can be reliably
detected were five copies per reaction.
Statistical analysis
For statistical analysis, Student’s t-tests were carried out.
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